Aligos Therapeutics Announces Acceptance Of Five Abstracts At American Association For Study Of Liver Disease's The Liver Meeting
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts
Aligos got five of their research studies picked to show at a big doctor conference. This means scientists think their liver disease work is important enough to share with peers.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.